HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 drugs linked to lower dementia, stroke and mortality than other diabetes drugs

Louis Nervegna · Jul 18, 2025 · ♥ 13 reactions · 1 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Insulin resistance & diabetes
AI summary & key facts

Louis shares a JAMA summary stating that patients on semaglutide or tirzepatide had lower risks of dementia, stroke and all-cause mortality than those on other antidiabetic medications, and comments that calorie restriction works. The comment on calorie restriction is his interpretation.

Study after study keeps showing the same thing. It has become impossible to ignore this. Calorie restriction works.

#glp1HD #diabetesHD #calorierestrictionHD

Research cited

Patients treated with GLP-1 receptor agonists semaglutide or tirzepatide had lower risks of dementia, stroke, and all-cause mortality compared to those using other antidiabetic medications. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With… (JAMA Netw Open, 2025)

No photo description available.
← newer: Hashtag-only post on erythritol with unavailable shared contolder: L-carnitine supplements increased carotid plaque stenosis in →